Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The CIDI-core substance abuse and dependence questions: cross-cultural and nosological issues. The WHO/ADAMHA Field Trial.

Cottler LB, Robins LN, Grant BF, Blaine J, Towle LH, Wittchen HU, Sartorius N.

Br J Psychiatry. 1991 Nov;159:653-8.

PMID:
1756341
2.

WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results.

Ustün B, Compton W, Mager D, Babor T, Baiyewu O, Chatterji S, Cottler L, Göğüş A, Mavreas V, Peters L, Pull C, Saunders J, Smeets R, Stipec MR, Vrasti R, Hasin D, Room R, Van den Brink W, Regier D, Blaine J, Grant BF, Sartorius N.

Drug Alcohol Depend. 1997 Sep 25;47(3):161-9. Review. Erratum in: 1998 Apr 1;50(2):185-6.

PMID:
9306042
3.

Current concepts of addiction.

Jaffe JH.

Res Publ Assoc Res Nerv Ment Dis. 1992;70:1-21. Review. No abstract available.

PMID:
1535926
4.

Structure, content and reliability of the Munich-Composite International Diagnostic Interview (M-CIDI) substance use sections.

Lachner G, Wittchen HU, Perkonigg A, Holly A, Schuster P, Wunderlich U, Türk D, Garczynski E, Pfister H.

Eur Addict Res. 1998 Mar;4(1-2):28-41. Review.

PMID:
9740815
5.

Substance use disorder: abuse, dependence and dyscontrol.

Widiger TA, Smith GT.

Addiction. 1994 Mar;89(3):267-82. Review.

PMID:
8173493
6.
7.
8.

Substance use disorders in the DSM-IV.

Nathan PE.

J Abnorm Psychol. 1991 Aug;100(3):356-61. Review.

PMID:
1918614
9.

[Diagnostic structured interviews in child and adolescent's psychiatry].

Renou S, Hergueta T, Flament M, Mouren-Simeoni MC, Lecrubier Y.

Encephale. 2004 Mar-Apr;30(2):122-34. Review. French.

PMID:
15107714
11.

The antisocial personality disorder diagnosis in substance abusers: problems and issues.

Alterman AI, Cacciola JS.

J Nerv Ment Dis. 1991 Jul;179(7):401-9. Review.

PMID:
1869868
12.

Importance of clinical diagnoses for comorbidity studies in substance use disorders.

Torrens M, Martin-Santos R, Samet S.

Neurotox Res. 2006 Dec;10(3-4):253-61. Review.

PMID:
17197374
13.

[Pharmacotherapy of substance dependence and withdrawal syndromes].

Walter M, Wiesbeck GA.

Ther Umsch. 2009 Jun;66(6):449-57. doi: 10.1024/0040-5930.66.6.449. Review. German.

PMID:
19496041
14.

The psychometric properties of the Composite International Diagnostic Interview.

Andrews G, Peters L.

Soc Psychiatry Psychiatr Epidemiol. 1998 Feb;33(2):80-8. Review.

PMID:
9503991
15.

DSM-5 criteria for substance use disorders: recommendations and rationale.

Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF.

Am J Psychiatry. 2013 Aug;170(8):834-51. doi: 10.1176/appi.ajp.2013.12060782. Review.

16.

Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10?

Hughes JR, Oliveto AH, Helzer JE, Higgins ST, Bickel WK.

Am J Psychiatry. 1992 Jan;149(1):33-40. Review.

PMID:
1728182
17.

Neurological complications of substance abuse.

Brust JC.

Res Publ Assoc Res Nerv Ment Dis. 1992;70:193-203. Review. No abstract available.

PMID:
1535931
18.

DSM-IV substance use disorders: the view from DSM-III-R.

Rounsaville BJ.

NIDA Res Monogr. 1992;119:101-5. Review. No abstract available.

PMID:
1435963
19.
20.

New Drugs of Abuse and Withdrawal Syndromes.

Andrabi S, Greene S, Moukaddam N, Li B.

Emerg Med Clin North Am. 2015 Nov;33(4):779-95. doi: 10.1016/j.emc.2015.07.006. Review. Erratum in: Emerg Med Clin North Am. 2016 Feb;34(1):xv. Moukkadam, Nidal [corrected to Moukaddam, Nidal].

PMID:
26493523
Items per page

Supplemental Content

Write to the Help Desk